Literature DB >> 30361826

Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report.

Ekjot Kaur1,2, Jayant S Goda2,3, Atanu Ghorai1,2, Sameer Salunkhe1,2, Prakash Shetty2,4, Aliasgar V Moiyadi2,4, Epari Sridhar2,5, Abhishek Mahajan2,3, Rakesh Jalali2,3, Shilpee Dutt6,7.   

Abstract

PURPOSE: Previously we have shown, using a primary glioblastoma (GBM) cell model, that a subpopulation of innately radiation resistant (RR) GBM cells survive radiotherapy and form multinucleated and giant cells (MNGCs) by homotypic fusions. We also showed that MNGCs may cause relapse. Here, we set out to explore whether molecular characteristics of RR cells captured from patient-derived primary GBM cultures bear clinical relevance.
METHODS: Primary cultures were derived from 19 naive GBM tumor samples. RR cells generated from these cultures were characterized using various cell biological assays. We also collected clinicopathological data of the 19 patients and assessed associations with RR variables using Spearman's correlation test and with patient survival using Kaplan-Meier analysis. Significance was determined using a log-rank test.
RESULTS: We found that SF2 (surviving fraction 2) values (p = 0.029), days of RR cell formation (p = 0.019) and percentage of giant cells (p = 0.034) in the RR population independently correlated with a poor patient survival. We also found that low ATM (Ataxia-telangiectasia mutated) expression levels in RR cells showed a significant (p = 0.002) negative correlation with SF2 values. A low ATM expression level in RR cells along with a high tumor volume was also found to negatively correlate with patient survival (p = 0.011). Finally, we found that the ATM expression levels in RR cells independently correlated with a poor patient survival (p = 0.014).
CONCLUSIONS: Our data indicate that molecular features of innately radiation resistant GBM cells independently correlate with clinical outcome. Our study also highlights the relevance of using patient-derived primary GBM cultures for the characterization of RR cells that are otherwise inaccessible for analysis.

Entities:  

Keywords:  ATM; DNA repair; Glioblastoma; MNGCs; Patient-derived primary cultures; Radiation resistant cells

Mesh:

Year:  2018        PMID: 30361826     DOI: 10.1007/s13402-018-0411-7

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   7.051


  31 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  Clonogenic assay of cells in vitro.

Authors:  Nicolaas A P Franken; Hans M Rodermond; Jan Stap; Jaap Haveman; Chris van Bree
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 3.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

4.  Breast carcinoma with tumor giant cells. Report of a case with fine needle aspiration cytology.

Authors:  A G Douglas-Jones; W T Barr
Journal:  Acta Cytol       Date:  1989 Jan-Feb       Impact factor: 2.319

5.  Radiation-induced homotypic cell fusions of innately resistant glioblastoma cells mediate their sustained survival and recurrence.

Authors:  Ekjot Kaur; Jacinth Rajendra; Shailesh Jadhav; Epari Shridhar; Jayant Sastri Goda; Aliasgar Moiyadi; Shilpee Dutt
Journal:  Carcinogenesis       Date:  2015-04-11       Impact factor: 4.944

6.  Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases.

Authors:  Anil V Parwani; Mehsati Herawi; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

7.  Endometrial adenocarcinoma with a component of giant cell carcinoma.

Authors:  M A Jones; R H Young; R E Scully
Journal:  Int J Gynecol Pathol       Date:  1991       Impact factor: 2.762

Review 8.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

9.  Immunohistochemical study of giant cell in glioblastoma.

Authors:  H Kawano; T Kubota; K Sato; T Goya; S Arikawa; S Wakisaka
Journal:  Clin Neuropathol       Date:  1995 Mar-Apr       Impact factor: 1.368

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  3 in total

1.  Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.

Authors:  Ekjot Kaur; Jyothi Nair; Atanu Ghorai; Saket V Mishra; Anagha Achareker; Madhura Ketkar; Debashmita Sarkar; Sameer Salunkhe; Jacinth Rajendra; Nilesh Gardi; Sanket Desai; Prajish Iyer; Rahul Thorat; Amit Dutt; Aliasgar Moiyadi; Shilpee Dutt
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

Review 2.  Giants and monsters: Unexpected characters in the story of cancer recurrence.

Authors:  Shai White-Gilbertson; Christina Voelkel-Johnson
Journal:  Adv Cancer Res       Date:  2020-05-04       Impact factor: 6.242

3.  Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation.

Authors:  Christos E Zois; Anne M Hendriks; Syed Haider; Elisabete Pires; Esther Bridges; Dimitra Kalamida; Dimitrios Voukantsis; B Christoffer Lagerholm; Rudolf S N Fehrmann; Wilfred F A den Dunnen; Andrei I Tarasov; Otto Baba; John Morris; Francesca M Buffa; James S O McCullagh; Mathilde Jalving; Adrian L Harris
Journal:  Cell Death Dis       Date:  2022-06-28       Impact factor: 9.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.